Overview
Golimumab is a fully human anti-TNF-α monoclonal antibody approved specifically for ulcerative colitis (the only anti-TNF in IBD given as a monthly subcutaneous injection). It is also approved for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Key Uses
Moderate-to-severe ulcerative colitis (not approved for Crohn's disease)
Convenient once-monthly subcutaneous injection for maintenance
Also approved for rheumatoid arthritis and spondyloarthropathies
How It Works
Fully human antibody that binds both soluble and membrane-bound TNF-α
Induction: 200 mg SC at week 0, then 100 mg at week 2; maintenance: 100 mg SC every 4 weeks
SmartJect autoinjector makes self-injection straightforward
Safety & Self-Care
TB and hepatitis B screening before starting
Report infection signs immediately
Avoid live vaccines during treatment
Once-monthly dosing — set a monthly reminder to stay on schedule
Store in refrigerator; allow to reach room temperature before injecting
Contact Your IMCC Team
Contact your IMCC team if symptoms worsen, you develop infection, or before any surgery or pregnancy planning.
Share this with someone who needs it: